Navigation Links
Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
Date:10/29/2009

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Novartis Pharma AG has decided not to exercise its option to license IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. As a result, Idenix retains the worldwide rights to develop, commercialize and license IDX184 without any further obligation to Novartis.

"As we continue to develop IDX184, we look forward to seeking a partner that will assist us in maximizing the value of this asset," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix.

About IDX184

IDX184 is a novel, liver-targeted 2'-methyl guanosine nucleotide prodrug, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
5. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
9. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
10. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
11. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 Continental Clinical Solutions, ... into clinical trials at its mid-Atlantic late-phase research ... was created with the idea of closing patient ... role in medical advances," said Continental's CEO, ... to the immortal cell line of Henrietta Lacks, ...
(Date:11/24/2014)... 24, 2014 The new video, ... METTLER TOLEDO demonstrates how to reduce the number ... and sample panel design can be complicated, requiring ... protect against corrosion and deposition. Dedicated single and ... amount of panel space. Additionally, installing and maintaining ...
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... Two new educational webinars hosted by DrugDev ... research and how the pharmaceutical industry can make life easier ... Where Does the ALS Money Go? , Featuring guest speaker ... 1:30pm ET, Register to attend , This webinar ... Julianne Dorn Professor of Neurology at Massachusetts General Hospital at ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2
... PAREXEL International,Corporation (Nasdaq: PRXL ) announced ... Small-Cap Growth Stock Conference in New York, NY. ... will be making,a formal presentation on PAREXEL at ... A live webcast of this presentation will be ...
... G2 approved by leading European authority on natural/ ... CALGARY, Oct. 6 /PRNewswire-FirstCall/ - Botaneco Specialty ... (SemBioSys), today,announced that its second generation oleosome product, ... approved raw material, complying with,the standards for ecological ...
... Galenea Corp. and,Otsuka Pharmaceutical Co., Ltd. announced today ... collaboration. The two companies have,been working together since ... schizophrenia and other central nervous system (CNS),diseases. The ... of the initial,five-year alliance and brings the total ...
Cached Biology Technology:PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 3Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration 2Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration 3
(Date:11/4/2014)... of Madagascar,s 101 species of lemurs are threatened with ... rainforests they call home. A new study by Rice ... on rainforest tree populations, which raises concerns about the ... rich biodiversity. , A large proportion of trees in ... in turn disperse the seeds of their fruit trees ...
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... in cells normally perform only one job, but a new ... out how to recruit enzymes for other jobs to benefit ... have one biological function in a cell, but many are ... those at the beginning of a chemical reaction ...
... tropical South Atlantic Ocean can be used to accurately ... of miles away in northwestern India, a University of ... Colder-than-normal July sea surface temperatures in the tropical South ... malaria epidemics in the arid and semi-arid regions of ...
... has discovered mutations in two genes that lead to the ... known as Lou Gehrig,s disease, and related degenerative diseases. ... the abnormal build-up of the proteins inside cells. These proteins ... also been linked to cancer, including the Ewing sarcoma, the ...
Cached Biology News:Promiscuous enzymes may be recruited to aid industry, medical fields 2Early warning system provides 4-month forecast of malaria epidemics in northwest India 22 new genes linked to amyotrophic lateral sclerosis and related disorders 22 new genes linked to amyotrophic lateral sclerosis and related disorders 3
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Biology Products: